Macro Challenges Make Calls On Newly Resilient Medtechs

Health Care Transition Accelerates And Sustainability Compliance Is Demanding Attention

 
• By Ashley Yeo
  
Generate a summary of this article
Listen to this article
Beta

Global medtechs had a big enough challenge with COVID-19 and its aftermath before the full-scale regional conflict in Ukraine added more uncertainty to the question of when market normality would return.

sustainability
• Source: Shutterstock

For medtechs, 2022 will be remembered as one of the most challenging years the industry has seen in decades. The COVID-19 pandemic continued to impact operations for much of the year – especially in China – and disrupted supply chains. In addition, soaring inflation and rising interest rates combined to test the industry’s resilience and drag a big shadow over the global economic outlook.

That was how the ostomy and wound care products company Coloplast Ltd. described the events of 2021-2022. But these...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from ESG

How to create a story in Arc

 
• By Kosh Naran

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, In Vivo investigates.

Podcast: Thermo Fisher’s Meron Mathias On Why Environmental Sustainability Must Be A Top Priority

 
• By Ashley Yeo

Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.

Podcast: Thermo Fisher’s Meron Mathias On Why Environmental Sustainability Must Be A Top Priority

 
• By Ashley Yeo

Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.

Boehringer R&D Exec: ‘People Are Longing For Connection’

 
• By Dean Rudge

In her role as Boehringer's senior vice president and global head of Development Sciences, Xiaorong He emphasizes patient-centric innovation and sustainability. She is committed to incorporating patient insights into product development and advancing eco-friendly practices within the company's R&D pipeline.  

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By Saba Afreen

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By Saba Afreen

XXXXtesting